Hemostatic Disorders 
Welcome,         Profile    Billing    Logout  

9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hemostatic Disorders
Myeloma XI, NCT01554852 / 2009-010956-93: Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients

Checkmark From P3 Myeloma XI trial in NDDM at ASH 2016
Dec 2016 - Dec 2016: From P3 Myeloma XI trial in NDDM at ASH 2016
Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Active, not recruiting
3
4420
Europe
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Revlimid (lenalidomide), Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen, Kyprolis (carfilzomib), Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen, Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen, Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen, Velcade (bortezomib), Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance, Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance, Zolinza (vorinostat), High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)
University of Leeds, Celgene, Merck Sharp & Dohme LLC, Amgen
Multiple Myeloma
12/21
12/22
NCT01754402: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Active, not recruiting
1/2
56
US
Bendamustine, Treanda, Bendeka, Pomalidomide, CC-4047, Pomalyst, Dexamethasone
Cristina Gasparetto, Celgene
Multiple Myeloma
12/16
01/25
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.

No Longer Available
N/A
US
Plerixafor, AMD3100, Mozobil
Genzyme, a Sanofi Company
Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
 
 
NCT00999414: UARK 2009-32 Compassionate Use Study of Carfilzomib

No Longer Available
N/A
US
Carfilzomib
University of Arkansas, Onyx Therapeutics, Inc.
Multiple Myeloma
04/15
04/15
NCT02541643: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

No Longer Available
N/A
US
Elotuzumab, BMS-901608
Sundar Jagannath, Bristol-Myers Squibb
Multiple Myeloma
 
 
NCT00799539: A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

No Longer Available
N/A
Canada
bortezomib, melphalan, prednisone
Janssen-Ortho Inc., Canada, Ortho Biotech Canada
Multiple Myeloma
 
 
NCT02204553: Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

No Longer Available
N/A
US
Panobinostat
Novartis Pharmaceuticals
Multiple Myeloma
 
 
NCT02666209: Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

No Longer Available
N/A
US
Ulocuplumab, BMS-936564, Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Decadron
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Multiple Myeloma in Relapse, Multiple Myeloma
 
 
NCT02751554: PET Imaging of Patients Using 124I-PU-AD

Recruiting
N/A
10
US
124I-PU-AD, PET Scan, Blood draws
Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Rockefeller University, Samus Therapeutics, Inc.
Solid Malignancy, Lymphoma, Multiple Myeloma, Alzheimer's Disease
04/18
08/18

Download Options